(1S,2S,5R,6S)-2-[2(S)-Aminopropionamido]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride
- In recent years, with the repeated cloning of glutamate receptor genes, it has become clear that there are surprisingly many subtypes of glutamate receptors. At present, glutamate receptors are broadly classified into two types: the “ionotropic type”, in which the receptor has an ion channel structure, and the “metabotropic type”, in which the receptor is coupled to G-proteins (Science, 258, 597-603, 1992). Ionotropic receptors are classified pharmacologically into three types: N-methyl-D-asparaginic acid (NMDA), α-amino-3-hydroxy-5-methyl isoxazole-4-propionate AMPA), and kynate (Science, 258, 597-603, 1992). Metabotropic receptors are classified into eight types, type 1 through type 8 (J. Neurosci., 13, 1372-1378, 1993; Neuropharmacol., 34, 1-26, 1995).
- The metabotropic glutamate receptors are classified pharmacologically into three groups. Of these, group 2 (mGluR2/mGluR3) bind with adenylcyclase, and inhibit the accumulation of the Forskolin stimulation of cyclic adenosine monophosphate (cAMP) (Trends Pharmacol. Sci., 14, 13 (1993)), which suggests that compounds that act on group 2 metabotropic glutamate receptors should be useful for the treatment or prevention of acute and chronic psychiatric and neurological disorders. As a substance that acts on group 2 metabotropic glutamate receptors, (+)-(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid has been disclosed in Japanese Unexamined Patent Publication, No. Hei 8-188561 .
- Fluorine atoms tend to be strongly electron-attractive and to confer high fat solubility, and compounds into which fluorine atoms are introduced greatly change their physical properties. Thus introducing fluorine atoms might greatly affect the absorbability, metabolic stability, and pharmacological effects of a compound. But it is by no means easy to introduce fluorine atoms. In fact, Japanese Unexamined Patent Publication No. Hei 8-188561  does not even discuss the introduction of fluorine atoms into (+)-(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid.
Org Process Res Dev 2006, 10(1): 28
Drugs Fut 2002, 27(Suppl. A): Abst C39
241st ACS Natl Meet (March 27-30, Anaheim) 2011, Abst MEDI 163
J Pharm Sci 2010, 99(3): 1574
J Med Chem 2005, 48(16): 5305
Tetrahedron Lett 2005, 46(43): 7299
24th CINP Congr (June 20-24, Paris) 2004, Abst P02.269
|WO2000004010A1*||Jul 14, 1999||Jan 27, 2000||Stephen Richard Baker||Bicyclohexane derivatives|
|EP0696577A1 *||Aug 11, 1995||Feb 14, 1996||Eli Lilly And Company||Synthetic excitatory amino acids|
|EP1052246A1 *||Jan 27, 1999||Nov 15, 2000||Taisho Pharmaceutical Co. Ltd||Fluorine-containing amino acid derivatives|